

Pre-Application Information

Notice of Special Interest: R13 Support for Conferences and Scientific Meetings to Support Consensus Building for Autoimmune Disease Research Related Common Data Elements

Dr. Vicki Shanmugam
Director
Office of Autoimmune Disease Research

Dr. Carmen Ufret-Vincenty
Program Officer
Office of Autoimmune Disease Research

October 2024



Facebook: /NIHORWH

X: @NIH_ORWH



OADRInfo@nih.gov




orwh.od.nih.gov/OADR-ORWH

Notice of Special Interest: R13 Support for Conferences and Scientific Meetings to Support Consensus Building for Autoimmune Disease Research Related Common Data Elements (NOT-OD-24-145)

- **Objective:** To highlight interest in receiving applications to stimulate development of NIH-endorsed common data elements (CDEs) applicable to autoimmune diseases through convening members of the scientific, clinical, patient, and advocate community to inform discussions
- **Funds Available and Anticipated Number of Awards:** Subject to availability of funds and institute, center, and office collaboration
- **Expiration Date:** December 14, 2026
- **Associated To:** NOFO PA-25-080 NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed) or any reissues – provides submission instructions
- **Award Project Period:** 1 year

Notice of Special Interest:
R13 Support for Conferences and
Scientific Meetings to Support
Consensus Building for Autoimmune
Disease Research Related Common
Data Elements




[NOT-OD-24-145](#)

Notice of Special Interest: R13 Support for
Conferences and Scientific Meetings to Support
Consensus Building for Autoimmune Disease
Research Related Common Data Elements

NIH-Endorsed Common Data Elements (CDEs)



- A **Common Data Element** (CDE) is a standardized, precisely defined question, paired with a set of allowable responses, used systematically across different sites, studies, or clinical trials to ensure consistent data collection.
- Multiple CDEs (from one or more Collections) can be curated into **Forms**. Forms in the NIH Repository might be original or might recreate the format of real-world data collection instruments or case report forms.
- NIH has endorsed collections of CDEs that meet established criteria. **NIH-endorsed CDEs** are designated with a gold ribbon.
- The purpose of this endorsement is to facilitate data sharing and harmonize CDE across datasets, so that data sharing according to the 2023 [NIH Data Management and Sharing Policy](#) is possible by making data from different studies more interoperable.



[NIH CDE Repository](#)

What Applications Will Be Considered Responsive?

- The **final product must be CDEs** that the community has come to consensus on to be submitted for endorsement by the NIH CDE Governance Committee. This must include:
 - Clear definition of the variable(s) as a specified question and a permissible type, set, or range of answers
 - Documented evidence of reliability
 - Human- and machine-readable format
 - Clear licensing and intellectual property status
 - Recommended or designated by a recognized NIH body
- The conference(s)/meeting(s) should convene experts and partners to **drive consensus building** to arrive at agreed upon endorsable CDEs.
- Successful applicants are expected to work in consultation with the administering institute program staff to ensure CDEs developed meet the requirements of the NIH CDE Governance Committee.
- **The goal of these awards is bringing the community to consensus on CDEs to move forward for endorsement, which is distinct from most R13s where the meeting is the final product itself.**




[Autoimmune Disease Research Across NIH](#)

What Types of Conferences Are Considered Responsive?

- The NOSI **does not require a specific format** for the conference(s)/meeting(s).
- The applicant designs the format they consider has the highest probability of success based on the objective of this NOSI. The important thing is that it is **appropriately explained in the application**.
- **Perspectives to consider** for working groups, committees, meetings/conferences, and similar:
 - Clinicians and scientists
 - People living with autoimmune diseases, caregivers, and advocacy groups
 - People with autoimmune diseases must have a voice in the discussion and consensus building
- **Example formats** for consensus building among partners
 - Series of virtual-only meetings
 - 1-day consensus decision making in-person meeting
 - In-person consensus first, then multiple virtual meetings
- **A conference focusing only on discussing the state of the field or the importance of developing CDEs will be considered non-responsive.**

Refer to R13 NOFO PA-25-080 for Instructions To Submit


- **Objective in the Context of NOSI:** To support high quality conference(s)/ meeting(s) for developing endorsable CDEs for autoimmune disease research.
- **Advance Permission is Required:** Needs to be requested from both the OADR-ORWH and administering institute no later than 6 weeks before the application due date.
- **Submission:** Follow the Research (R) Instructions in the [How to Apply - Application Guide](#) except where the NOFO instructs to do otherwise.
- **Important NOFO-Specific Instructions:**
 - Attaching a Cover Letter that includes both the OADR-ORWH and administering institute “permission to submit” letters is required.
 - A Diversity Plan is required. If missing, the application will not be accepted.
 - Research Strategy Section becomes the Conference Plan.
- Refer to Parent R13 **NOFO PA-25-080** or any reissues.



[PA-25-080](#)
NIH Support for
Conferences and
Scientific Meetings

Reissuance of Funding Opportunities

- Funding opportunities may be periodically reissued. For example, PA-25-080 is a reissue of PA-24-141.
- If you see an **expiration banner** at the top of a funding opportunity (orange bar)




This notice has expired. Check the NIH Guide for active opportunities and notices.

Department of Health and Human Services

Part 1. Overview Information

scroll down to the **Related Notices section to find the reissuance** (orange boxes)



Related Notices

See [Notices of Special Interest](#) associated with this funding opportunity

- **October 02, 2024** This PAR has been reissued as [PA-25-080](#).
- **September 4, 2024** - Notice of Participation of the National Institute of Nursing Research (NINR) in PA-24-141, "NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)". See Notice [NOT-NR-24-010](#).
- **July 22, 2024** - Notice of Change in Information for PA-24-141. See Notice [NOT-OD-24-102](#).
- **March 12, 2024** - NIDCR Notice of Participation in PA-24-141 "NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)". See Notice [NOT-DE-24-018](#)
- **March 8, 2024** - Notice of NHLBI Participation in PA-24-141 "NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)". See Notice [NOT-HL-24-006](#).

As an Applicant, How Do I Get Started?

- **Write the Specific Aims** (limited to 1 page), including:
 - The disease area of focus
 - Landscape analysis of the current state of the field (check the [list of NIH-endorsed CDEs](#) to ensure you are planning to work on new CDEs)
 - Specific details (e.g., Delphi exercise or other consensus building approach) about the work that will be done to bring the community to consensus around specific components of CDEs not currently endorsed by NIH
- **Reach out to the team of experts and partners** you are planning to include.
- **Reach out to colleagues** who have successfully competed for R13 funding.
- **Email OADRinfo@nih.gov** no later than 6 weeks before the application due date to request a meeting to discuss your planned submission:
 - Include your Specific Aims.
 - This meeting is required to request permission to submit.
 - More than 1 meeting might be needed before permission to submit is granted.

How Do I Prepare for Meeting with OADR-ORWH and Administering Institute?

- Confirm that all **Key Players will attend the meeting.**
- Have the team **carefully read** and understand the:
 - NOSI – conference's/meetings' final product must be endorsable CDEs that the community has come to consensus on to be submitted for endorsement by the NIH CDE Governance Committee
 - Background information on CDEs – [definition and NIH CDE endorsement process](#)
- **Decide who will submit the application**, both the PI and the organization:
 - If possible, select someone with expertise to avoid mistakes that result in the application not being moved forward to NIH review.
 - If first time submitting an R13 application, partner with colleagues who have successfully competed for R13 funding.
- Have a cohesive plan with your team to discuss the **Specific Aims** in detail.
- Have a clear idea of your **Diversity Plan** (a requirement for R13s to be moved forward to NIH review) — not just representation, but true engagement.

“Permission to Submit” Was Granted – What Comes Next?

- You will receive letters documenting “permission to submit” from both OADR-ORWH and the administering institute. File them appropriately since they must be included in the cover letter attachment. **Applications missing one or both "permission to submit" letters will not be accepted.**
- Please re-read the NOSI and NOFO before you start writing. Your application will be evaluated based on R13 review criteria and responsiveness to the NOSI (developing endorsable CDEs and bringing the community to consensus).
 - Follow **all submission instructions**.
 - **NOFO Section V** explains in detail how your application will be reviewed.
 - **NOFO Section VII** provides contacts for help with the submission process.
- Please make sure to **follow all recommendations and instructions** provided by the OADR-ORWH team and administering institute when writing your application.

The SF424 (R&R) General Application Guide
and special submission requirements
for this NOSI

Sample: Table of Contents for a NEW R13 Application

- SF 424 R&R Cover Page ([SF424 Receipt and Referral \(R&R\) Application for Federal Assistance Form with Instructions](#))
 - Table of Contents
- Performance Sites ([Project/Performance Site Location\(s\) Form and Instructions](#))
- Research & Related Other Project Information ([R&R Other Project Information Form and Instructions](#))
 - Project Summary/Abstract (Description) (30 lines of text)
 - Project Narrative (3 sentences)
 - Facilities & Other Resources
 - Other Attachments
 - Diversity Plan (unique to R13 applications – 1-page limit)
- Research & Related Senior/Key Person ([R&R Senior/Key Person Profile Form and Instructions](#); biosketches are attached here – 5-page limit for each biosketch)

Sample: Table of Contents for a NEW R13 Application (cont.)

- Research & Related Budget Year 1 ([R&R Budget Form and Instructions](#))
- Budget Justification (entered in R&R Budget Form)
- Research & Related Cumulative Budget (entered in R&R Budget Form)
- PHS398 Cover Page Supplement ([PHS 398 Cover Page Supplement Form and Instructions](#))
- PHS 398 Research Plan (Specific Aims, Conference Plan, and Letters of Support are attached using the [PHS 398 Research Plan Form and Instructions](#))
 - Specific Aims (1-page limit)
 - Conference Plan, entered under Research Strategy (6-page limit)
 - PHS Human Subjects and Clinical Trials Information ([PHS Human Subjects and Clinical Trials Information Form and Instructions](#))
 - Bibliography & References Cited (entered in R&R Other Project Information Form)
 - Letters of Support (if included)

Other Requirements Might Apply

- The Sample Table of Contents is meant as an example of what a new R13 application might look like. For the application to be considered complete, it **must contain at least the sections provided in the Sample**.
- However, **other sections might also be required** for resubmissions, revisions, or other special circumstances.
- All **rules in Parent R13 NOFO apply** to this submission. Make sure to refer to the Parent R13 NOFO and confirm that all sections required for your situation are included in your submission.
- All **required sections must be completed** for the application to be moved forward to NIH review.

How Do I Submit an Application in Response to This NOSI?

- NOT-OD-24-145 must be entered in the **Agency Routing Identifier field (box 4b)** of the SF424 Receipt and Referral (R&R) Application for Federal Assistance Form (see orange arrows).

The image shows a screenshot of the SF 424 (R&R) Application for Federal Assistance Form. At the top left is a button labeled "View Burden Statement". To the right, it says "OMB Number: 4040-0001" and "Expiration Date: 10/31/2019". The title "APPLICATION FOR FEDERAL ASSISTANCE SF 424 (R&R)" is prominently displayed. Below the title, section "1. TYPE OF SUBMISSION" contains three radio button options: "Pre-application", "Application", and "Changed/Corrected Application". The "Pre-application" option is highlighted with a red border. Section "2. DATE SUBMITTED" and "Applicant Identifier" each have a text input field. Section "3. DATE RECEIVED BY STATE" has a text input field. Section "4." contains three sub-items: "a. Federal Identifier" with a text input field, "b. Agency Routing Identifier" with a large text input field, and "c. Previous Grants.gov Tracking ID" with a text input field. Two large orange arrows point towards the "Agency Routing Identifier" field (box 4b), one from the left and one from the right, indicating where the number NOT-OD-24-145 should be entered.

- If NOT-OD-24-145 is not entered in box 4b, the application will not be considered for this initiative.

How Do I Include the “Permission to Submit” Letters?

- The 2 letters documenting “permission to submit” your application (from OADR-ORWH and the administering institute) must be combined with a cover letter into 1 PDF file. **The 2 letters must be included in your cover letter for the application to be moved forward to NIH Review.**
- “Permission to submit” letters for a new application cannot be recycled for a resubmission or revision. Rather, **a new letter is required for resubmission or revision.** Confirm that you are submitting the correct 2 letters documenting “permission to submit” from OADR-ORWH and the administering institute.
- “Permission to submit” an application **does not guarantee that the application will be moved forward to NIH review.** Only applications deemed as responsive to the terms of both this NOSI and the Parent R13 NOFO will be moved forward to NIH review and considered for this initiative.
- **“Permission to submit” an application does not guarantee funding.**

Format and Submission of the Cover Letter

- Add the **cover letter as an attachment** in the correct location of the [SF424 R&R Application for Federal Assistance Form](#) [page 2; 21. Cover Letter Attachment (orange rectangle)].

20. Pre-application		Add Attachment	Delete Attachment	View Attachment
21. Cover Letter Attachment		Add Attachment	Delete Attachment	View Attachment

- The cover letter, addressed to the Division of Receipt and Referral, should contain the following elements combined into 1 PDF file:
 - A letter that includes the **application title, title and number of the NOFO and NOSI, and a statement that you have attached the required documentation** (the 2 letters documenting “permission to submit” as required by NOFO and NOSI).
 - **2 “permission to submit” letters.**
- **The cover letter is for administrative use only.** It will not become part of the assembled application or shared with peer reviewers.

What Do I Need To Know About the Diversity Plan? Format and Submission

- **If the Diversity Plan is missing, your application will not be reviewed.**
- Required file name: **DiversityPlan.pdf** (no spaces). If the file name is changed, the platform will not recognize that the Diversity Plan is present in the assembled application, which Grants.gov will interpret as a submission error, and the application will not move forward to Receipt and Referral for further consideration. Submit the Diversity Plan using **Field 12. Other Attachments** in the Research [R&R Other Project Information Form](#).
- Limited to **1-page in length**.
- During review, the Diversity Plan will be **evaluated based on how it demonstrates efforts to enhance diversity and increase participation of individuals from diverse backgrounds** (including underrepresented groups) in the planning, implementation and engagement in the proposed conference/meeting(s). See NOFO Section V (Additional Review Criteria).

What Do I Need To Know About the Diversity Plan? Content


- Specifically describe plans to enhance diversity **by increasing the participation of individuals from diverse backgrounds**, including those from underrepresented groups (e.g., underrepresented racial and ethnic groups, individuals with disabilities, individuals from disadvantaged backgrounds, and women), people living with autoimmune diseases, advocacy groups, and caregivers in the selection of and/or the makeup of:
 - Organizing committee
 - Speakers
 - Invited participants (e.g., session chairs, panel discussants)
- Demonstrate the **mechanisms that will support representation and engagement** (e.g., childcare, lactation spaces).
- Applicants should consider the geographical conference area from where anticipated participants will come, the expected size and composition of the audience, as well as the method of selection in describing efforts under the Diversity Plan and how these efforts will be assessed afterwards. Where applicable, applicants should describe the success of previous strategies to enhance diversity in the planning and implementation of conferences.

Key Personnel: Think Carefully About Who To Bring to the Table

- Carefully consider the **different types of expertise needed** in the context of the disease area of focus (e.g., clinicians, scientists, clinical research coordinators, epidemiologists, data scientists and/or statisticians, people living with autoimmune diseases, advocacy groups, caregivers).
- Ensure that there is **balanced and adequate representation** of different perspectives in the field, including the voice of people living with autoimmune diseases and caregivers.
- Grants.gov requires a **valid Commons ID** for each Key Person in the application.
- For key participants who are not Key Personnel, **provide letters of support** documenting their participation when appropriate (e.g., speakers, presenters, session moderators, advocacy groups, people with autoimmune diseases, caregivers).

Biosketches: Important Content and Formatting Requirements

- NIH requires submission of a biosketch for each proposed senior/key person and other significant contributor(s) on a grant application. Ensure that you **use the current format for the biosketch** (use the non-fellowship template).
- Personal Statements in the biosketches must **describe how past experiences, training, and expertise** will contribute to consensus building, increasing the participation of individuals from diverse backgrounds, including those from underrepresented groups, and development of endorsable CDEs in the disease area of focus.
- Refer to [Formatting Requirements for Attachments](#) for instructions for formatting the PDF document prior to attaching it to the submission.



[Instructions for
Biosketch](#)

What Is Allowable in the Budget?

- Award period: 1 year.
 - If doing this type of project for the first time and unsure how it will evolve, you can **initially request 1 year of funding for a set of CDEs** and submit future applications for additional CDEs if appropriate.
 - If you are considering requesting multiple years of funding, this should be discussed during the meeting with OADR-ORWH and the administering institute. A **clear plan with concrete milestones of CDEs for each year** must be specified.
- Funds **can be applied to salary, conference facilities, online conference platforms** as appropriate. **Indirect costs are not allowed.** See NOFO Section IV for details.
- Award budget is **\$75,000 total costs** for 1 year of funding.
- **Provide a narrative justification** for each proposed personnel position, including the role of the individual in the conference and the proposed level of effort. Include information regarding efforts to obtain funding for this conference from other sources.
- Reminder: **final product must be endorsable CDEs** that the community has come to consensus on.

How Do I Write the Specific Aims?

- Consider if the Specific Aims discussed with OADR-ORWH and the administering institute need to be revised based on guidance provided. Confirm that the following has been appropriately described:
 - The **disease area of focus**
 - **Landscape analysis** of the current state of the field (refer to the [list of NIH-endorsed CDEs](#) to ensure you are planning to work on new ones)
 - Specific details (e.g., Delphi exercise or other consensus building approach) regarding the **work that will be done to bring the community to consensus around specific components of CDE development** being proposed
- Applicants are expected to work **in consultation with OADR-ORWH and administering institute program staff** to ensure CDEs developed meet the requirements of the NIH CDE Governance Committee.
- Keep in mind that reviewers will evaluate if the conference **addresses an important problem and how scientific knowledge or clinical practice will be advanced** (see NOFO Section V for details). The Specific Aims and Conference Plan should thoroughly address these points.
- Since the final product must be CDEs, **it is expected that the Specific Aims will focus on bringing the community together to build consensus and deliver endorsable CDEs**. It is up to the applicants how to strategize which CDEs to target and when.

What Information Is Needed for the Conference Plan?

- Start with **describing the approach** you propose to use to achieve endorsable CDEs (e.g., virtual, in-person, a combination of both) and the pre-work leading up to the conference/meeting(s) to facilitate CDE development (e.g., methodical review of relevant publications).
- **Describe the objectives, specific program, and logistical arrangements** for the conference/meeting(s).
- Outline the proposed agenda(s) and timeline with **concrete, achievable milestones for building consensus towards endorsable CDEs** during the period of the award.
- Provide a **detailed justification for the approach being taken** to build consensus around the specific CDEs proposed, including the scientific/clinical need, timeliness, and usefulness to the scientific community and people living with autoimmune diseases.

Additional Information Needed for the Conference Plan

- For in-person meetings, attendance for some individuals will be dependent on the availability of resources for family care. The application should **describe plans to identify resources for childcare and other types of family care at or near the conference/meeting site** to allow individuals with family care responsibilities to attend. The information should allow attendees to arrange for family care as needed. We strongly encourage that a hybrid option is available to account for unexpected events.
- **Describe the composition and role of the organizing committee**, and provide the names and credentials of key participants (i.e., speakers, presenters, session moderators, advocacy group representatives, people living with autoimmune diseases, caregivers), **including the basis for their selection**.
- **Describe how advocacy groups, caregivers and people living with autoimmune diseases will be part of this effort**. For example, it is important to garner input from people who are completing the CDE questionnaires (are they too burdensome and do the proposed CDEs measure what matters to them?).
- **Estimate anticipated geographic conference area** where participants will come from, the **expected size and composition** of the audience, as well as the **method of selection**.


Publicity of the Conference/Meeting(s) and Dissemination of the Final Product Are Part of the Conference Plan

- **Describe plans for publicizing the conference** to all interested participants (including people with autoimmune diseases, caregivers and advocacy groups) and, if applicable, for publishing the proceedings (note that publishing proceedings is not required but is strongly encouraged; publishing costs are an allowable expense).
- **Include specifics on groups, associations, institutions, among others, that will be contacted** in efforts to expand diverse participation of meeting moderators, speakers, and participants/attendees.
- **Identify related conferences held on the subject during the past 3 years** and how the proposed conference is similar to and/or different from these, and why it is still necessary and useful.

Common Pitfalls and Solutions

- If this is your first time submitting an R13, **partner with an institution that has successfully competed for R13 funding.**
- **Attachments must comply with formatting requirements** for the system to upload the PDF document, otherwise the system will not move the application forward to Receipt and Referral for review. For example,
 - File name character limits apply.
 - Hyperlinks can only be used for publication lists in the biosketch and are not allowed in any other section of the application.
 - Refer to [Formatting Requirements for Attachments](#) for detailed instructions.
- **Submit early and always view your application:**
 - View your assembled application and related documents using eRA Commons Status to confirm that nothing is missing and the application image was not corrupted.
 - Submit at least 2 days prior to the deadline to allow for corrections before the deadline.
 - The 2-day viewing window allows corrections but does NOT extend the deadline.
 - If an email from Grants.gov notifies you of submission errors, these must be resolved before the application moves forward from Grants.gov to Receipt and Referral.
 - If you do not see your application in eRA Commons, your application was not moved forward from Grants.gov to Receipt and Referral.

CSR Guidance for NIH Grant Applicants



CSR Resource Infographic

Applicable to All
Grant Submissions

✉ OADRInfo@nih.gov

🌐 orwh.od.nih.gov/OADR-ORWH

Resources and Programs for NIH Grant Applicants

From the Center for Scientific Review (CSR) of the National Institutes of Health (NIH)

NIH Center for Scientific Review

<https://public.csr.nih.gov>

CSR is the unit of NIH that oversees the first level of peer review for the majority of NIH grant applications, focusing on their scientific merit.

Note that CSR does not fund grants. In this infographic, we share some key information to assist scientists seeking NIH grants.

A GREAT PLACE TO BEGIN!

Subscribe to the *NIH Guide for Grants and Contracts* to stay abreast of new funding opportunities and policy changes that can impact your application:
<https://grants.nih.gov/funding/about-nih-guide-to-grants-and-contracts.htm>.

For Organization Administrative Offices:

- Start today! It can take six weeks or more for the authorizing official to complete required registrations:
- System for Award Management (SAM): required to do business with the federal government
- eRA Commons: required to do business with NIH
- Grants.gov: required to submit grant applications through the federal-wide grant portal
- Small Business Administration (SBA): required to participate in SBIR and STTR federal funding programs*
- Authorized organization representatives must submit grant applications on behalf of scientists.
- Learn about NIH submission policies including what to do if a federal system impacts your ability to submit on time.

For Scientists:

- Identify a notice of funding opportunity (NOFO) that fits your research by searching the *NIH Guide for Grants and Contracts* (see link above) and/or Grants.gov.
- If you don't have an eRA Commons account, work with your organization's account administrator to get one. eRA Commons IDs are required for all named personnel on an application and are needed to prepare your application if using the Application Submission System & Interface for Submission Tracking (ASSIST). Also, obtain an ORCID ID at <https://orcid.org>.
- Work with your administrative officials on a submission plan. Discuss submission system (ASSIST, Workspace, or institutional system), roles and responsibilities, and internal deadlines.
- Upon submission, use eRA Commons Status to view your assembled application image and related documents. Work with your administrative officials to correct any issues prior to the due date.
- Continue to use eRA Commons Status to track review assignments and outcomes.



Learn
More

- Organization Registrations: <https://grants.nih.gov/grants/how-to-apply-application-guide/prepare-to-apply-and-register/registration/org-representative-registration.htm>
- Submission Policies: <https://grants.nih.gov/grants/how-to-apply-application-guide/due-dates-and-submission-policies/submission-policies.htm>

- Find Grant Funding: <https://grants.nih.gov/funding/searchguide/index.html>
- eRA Overview: <https://www.era.nih.gov/help-tutorials/era-commons/overview.htm>
- Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs: <https://seed.nih.gov>

ESI RESOURCES

Are You an Early Stage Investigator (ESI)?

- You can extend your ESI status for certain life events, such as COVID, having a child, and health issues: <https://grants.nih.gov/policy/early-stage/index.htm>.



Are You an ESI Without Tenure? Consider CSR's Early Career Reviewer (ECR) Program.

- The program helps early career scientists become more competitive as grant applicants through first-hand experience with peer review.
- Consider enrolling in the program: <https://public.csr.nih.gov/ForReviewers/BecomeAREviewer/ECR>.

TIPS FOR SCIENTISTS

- Read and carefully follow all general application guide, NOFO-specific, and related NIH Guide notice instructions.
- Do not attempt to skirt page limits by re-homing information into non-limited sections. Your application could be withdrawn.
- Consult with experienced colleagues, but do not consider another investigator's application as a "written in stone" example of what to do, or not to do.
- Use the Assisted Referral Tool (ART) or Matchmaker to match your abstract or specific aims to a study section/scientific review group, scientific review officer (SRO), and program officer (PO): <https://art.csr.nih.gov/ART/selection.jsp>; <https://reporter.nih.gov/matchmaker>. You can also search study sections at the CSR website at <https://public.csr.nih.gov>.
- Use the Assignment Request Form to make suggestions for study section assignment—requests cannot be guaranteed, however. Please do not suggest reviewers. <https://www.niaid.nih.gov/grants-contracts/phs-assignment-request>.
- Be sure the targeted NIH institute or center (IC) participates in the NOFO; reach out to the IC PO before applying. If we cannot assign a funding IC, your application will not move forward. The #1 reason for withdrawal is submitting under a NOFO that the targeted IC does not participate in.
- Submit early to allow time to address unforeseen issues. Corrected submissions must be made by the deadline. The 2-day viewing window does not provide extra time beyond the deadline for corrections. CSR will not accept post-submission material to address errors or omissions.
- Some ICs provide sample applications and related documents: <https://grants.nih.gov/grants/how-to-apply-application-guide/resources/sample-applications.htm>.
- You can use NIH RePORTER (<https://reporter.nih.gov>) to search for NIH-funded colleagues from your institution. Seek them out for advice.
- Discuss your specific aims with the scientific/research contact named in the NOFO; check back in before submission, in case of changes in the IC's focus.
- When developing your application, consider seeking advice from faculty at your institution who have served as NIH peer reviewers. You may contact your grants office for this information. Do not contact current members of a study section to which your application is or might be assigned.

NIH SUBMISSION POLICIES

<https://grants.nih.gov/grants/how-to-apply-application-guide/due-dates-and-submission-policies/submission-policies.htm>

NEW!

Last Chance to Submit Data: Now you can submit new, late-breaking data up to 30 days before the review meeting: <https://grants.nih.gov/grants/guide/notice-files/NOT-OD-23-106.html>.

RESOURCES

General Resources:

- Navigating NIH: <https://public.csr.nih.gov/sites/default/files/2022-06/outreach-navigatingNIH-flyer.pdf>
- Research Training: <https://researchtraining.nih.gov>
- FAQs: <https://public.csr.nih.gov/sites/default/files/2022-06/outreach-FAQs-flyer.pdf>
- Integrity and Fairness in Peer Review: <https://public.csr.nih.gov/sites/default/files/2022-06/outreach-bias-flyer.pdf>
- Understanding Staff Roles: <https://grants.nih.gov/help/ic-staff-roles>

At CSR, We Care About Fairness:

- Bias Awareness and Mitigation training for reviewers and SROs
- Diversifying review panels
- Exploring blinded review processes
- Reporting avenues for unfair review (reportbias@csr.nih.gov) or review integrity breaches (csrrio@mail.nih.gov)
- Learn more: <https://public.csr.nih.gov/AboutCSR/Address-Bias-in-Peer-Review>

Select Grant Writing Resources:

- <https://grants.nih.gov/grants/how-to-apply-application-guide/format-and-write/write-your-application.htm>
- NIH Grant Writing Playlist (YouTube): https://youtube.com/playlist?list=PLOEUw5njvqBjGf6_OWtt-ueC2-ye0bK-
- NIH Grant Fundamentals Playlist (YouTube): https://youtube.com/playlist?list=PLOEUw5njvqBjGf6_OWtt-ueC2-ye0bK-

Talk to Us

Find submission help online at <https://www.era.nih.gov/need-help> or contact CSR's Division of Receipt and Referral (csrdrr@mail.nih.gov) for submission and assignment questions.

Questions about review assignment or the review process: Contact your SRO (contact information on the study section webpage, or in eRA Commons following assignment).

Questions about the alignment between your grant application and an IC's funding priorities, or guidance needed after reading your summary statement: Contact the PO noted on the NOFO.

Other questions? Contact the CSR Office of Communications and Outreach, at communications@csr.nih.gov.



NIH National Institutes of Health
Office of Autoimmune Disease Research
Office of Research on Women's Health

Due Dates

All applications are **due by 5:00 PM local time** of applicant organization.

NEW or Resubmission Due Date	Due Date to Request Approval to Submit	Earliest Project Start Date
12-Dec-24	31-Oct-24	Jul-25
12-Apr-25	1-Mar-25	Dec-25
12-Aug-25	1-Jul-25	Apr-24
12-Dec-25	31-Oct-25	Jul-26
12-Apr-26	1-Mar-26	Dec-26
12-Aug-26	1-Jul-26	Apr-27
12-Dec-26	31-Oct-26	Jul-27

[illegible]

Connect with us:

- OADRInfo@nih.gov
- www.orwh.od.nih.gov/OADR-ORWH
- www.nih.gov/women